Multiplex Assay Kit for Claudin 3 (CLDN3) ,etc. by FLIA (Flow Luminescence Immunoassay)

C7orf1; CPE-R2; CPETR2; HRVP1; RVP1; Clostridium Perfringens Enterotoxin Receptor 2; Ventral Prostate.1-Like Protein; CPE-Receptor 2

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Claudin 3 (CLDN3) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Claudin 3 (CLDN3) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Claudin 3 (CLDN3) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Claudin 3 (CLDN3) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 97-105 101
EDTA plasma(n=5) 84-102 89
heparin plasma(n=5) 86-93 89
sodium citrate plasma(n=5) 83-91 87

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Claudin 3 (CLDN3) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Claudin 3 (CLDN3) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Claudin 3 (CLDN3) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 79-90% 81-97% 82-93% 80-96%
EDTA plasma(n=5) 86-95% 85-96% 88-95% 95-104%
heparin plasma(n=5) 85-101% 97-105% 78-103% 79-94%
sodium citrate plasma(n=5) 88-96% 91-103% 79-90% 79-103%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:CLDN3) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Eur J Appl Physiol Gastrointestinal response and endotoxemia during intense exercise in hot and cool environments Pubmed: 23314685
European Journal of Applied Physiology Effects of probiotics supplementation on gastrointestinal permeability, inflammation and exercise performance in the heat Springer: Source
Pediatr Crit Care Med Clinical Characteristics Associated With Postoperative Intestinal Epithelial Barrier Dysfunction in Children With Congenital Heart Disease* PubMed: 25162512
Clinical Nutrition Reinforcement of intestinal epithelial barrier by arabinoxylans in overweight and obese subjects: A randomized controlled trial: Arabinoxylans in gut barrier. pubmed:28214040
Clinics and Research in Hepatology and Gastroenterology Plasma claudin-3 is associated with tumor necrosis factor-alpha-induced intestinal endotoxemia in liver disease Pubmed: 31053499
Nutrients Intestinal Permeability in Children with Celiac Disease after the Administration of Oligofructose-Enriched Inulin into a Gluten-Free Diet—Results of a Randomized … Pubmed: 32531982
Journal of Exercise Physiology Online Markers of Intestinal Damage in Individuals with and without Obesity during a 12-Week Exercise Period.
JACC: Basic to Translational Science Dysbiosis and Intestinal Barrier Dysfunction in Pediatric Congenital Heart Disease is Exacerbated Following Cardiopulmonary Bypass
Nutrients Short-Term Very High Carbohydrate Diet and Gut-Training Have Minor Effects on Gastrointestinal Status and Performance in Highly Trained Endurance Athletes Pubmed:35565896
Catalog No. Related products for research use of Rattus norvegicus (Rat) Organism species Applications (RESEARCH USE ONLY!)
RPF293Ra01 Recombinant Claudin 3 (CLDN3) Positive Control; Immunogen; SDS-PAGE; WB.
PAF293Ra01 Polyclonal Antibody to Claudin 3 (CLDN3) WB; IHC; ICC; IP.
MAF293Ra21 Monoclonal Antibody to Claudin 3 (CLDN3) WB; IHC; ICC; IP.
SEF293Ra ELISA Kit for Claudin 3 (CLDN3) Enzyme-linked immunosorbent assay for Antigen Detection.
LMF293Ra Multiplex Assay Kit for Claudin 3 (CLDN3) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.